Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael G Aman

Showing results (31-40 of 138) with videos related to

Pageof 14
Sort By:
Child and Adolescent Psychiatric Clinics of North America|September 9, 2008
Treatment of inattention, overactivity, and impulsiveness in autism spectrum disordersMichael G Aman, Cristan A Farmer, Jill Hollway, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 3, 2018
Dr. Handen et al. ReplyBenjamin L Handen, Jeremy Veenstra-VanderWeele, Evdokia Anagnostou, et al.
Journal of Autism and Developmental Disorders|May 13, 2009
A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disordersAnna J Esbensen, Jan S Greenberg, Marsha Mailick Seltzer, et al.
Journal of Autism and Developmental Disorders|February 1, 2005
Factor analysis of the Nisonger Child Behavior Rating Form in children with autism spectrum disordersLuc Lecavalier, Michael G Aman, David Hammer, et al.
The American Journal of Psychiatry|April 2, 2004
Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQRobert L Findling, Michael G Aman, Marielle Eerdekens, et al.
The American Journal of Psychiatry|August 3, 2002
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligenceMichael G Aman, Goedele De Smedt, Albert Derivan, et al.
Journal of Applied Behavior Analysis|July 22, 2005
Evaluation of pharmacological treatment of impulsivity in children with attention deficit hyperactivity disorderNancy A Neef, David F Bicard, Sayaka Endo, et al.
Journal of Child and Adolescent Psychopharmacology|October 27, 2010
Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorderMichael G Aman, William Kasper, George Manos, et al.
Intellectual and Developmental Disabilities|April 13, 2007
Project MED: effects of a Medication EDucation booklet series for individuals with intellectual disabilitiesMichael G Aman, Betsey A Benson, Cristan A Farmer, et al.
Therapeutic Drug Monitoring|August 30, 2012
Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescentsCatherine M T Sherwin, Shannon N Saldaña, Robert R Bies, et al.
Pageof 14

Showing results (31-40 of 138) with videos related to

Sort By:
Pageof 14
Child and Adolescent Psychiatric Clinics of North America|September 9, 2008
Treatment of inattention, overactivity, and impulsiveness in autism spectrum disordersMichael G Aman, Cristan A Farmer, Jill Hollway, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 3, 2018
Dr. Handen et al. ReplyBenjamin L Handen, Jeremy Veenstra-VanderWeele, Evdokia Anagnostou, et al.
Journal of Autism and Developmental Disorders|May 13, 2009
A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disordersAnna J Esbensen, Jan S Greenberg, Marsha Mailick Seltzer, et al.
Journal of Autism and Developmental Disorders|February 1, 2005
Factor analysis of the Nisonger Child Behavior Rating Form in children with autism spectrum disordersLuc Lecavalier, Michael G Aman, David Hammer, et al.
The American Journal of Psychiatry|April 2, 2004
Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQRobert L Findling, Michael G Aman, Marielle Eerdekens, et al.
The American Journal of Psychiatry|August 3, 2002
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligenceMichael G Aman, Goedele De Smedt, Albert Derivan, et al.
Journal of Applied Behavior Analysis|July 22, 2005
Evaluation of pharmacological treatment of impulsivity in children with attention deficit hyperactivity disorderNancy A Neef, David F Bicard, Sayaka Endo, et al.
Journal of Child and Adolescent Psychopharmacology|October 27, 2010
Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorderMichael G Aman, William Kasper, George Manos, et al.
Intellectual and Developmental Disabilities|April 13, 2007
Project MED: effects of a Medication EDucation booklet series for individuals with intellectual disabilitiesMichael G Aman, Betsey A Benson, Cristan A Farmer, et al.
Therapeutic Drug Monitoring|August 30, 2012
Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescentsCatherine M T Sherwin, Shannon N Saldaña, Robert R Bies, et al.
Pageof 14